Silo pharma announces positive results from ind-enabling study of sp-26 for fibromyalgia

Englewood cliffs, nj, march 15, 2023 (globe newswire) -- silo pharma, inc.  (nasdaq: silo) (“the company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has achieved positive results for its toxicology study of sp-26, its novel time-released, dosage-controlled formulation of ketamine. the study results evaluated the feasibility of using a rising dose design or maximum feasibility.
SILO Ratings Summary
SILO Quant Ranking